CIA
JAZZ icon

Concurrent Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Concurrent Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
+980
New +$215K ﹤0.01% 1846
2024
Q2 		– Sell
-5,824
Closed -$701K – 1043
2024
Q1 		$701K Buy
+5,824
New +$713K 0.03% 459

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Concurrent Investment Advisors's JAZZ Position: Q2 2026 in Review

Concurrent Investment Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 980 shares worth $236K. The stake represents ﹤0.01% of the portfolio and ranks #1846 among its holdings. This is a return to the name: Concurrent Investment Advisors previously reported a position in JAZZ as recently as Q1 2024.

Concurrent Investment Advisors first reported a position in JAZZ in Q1 2024 and has held it in 2 quarters since. The position peaked at $701K in Q1 2024. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Concurrent Investment Advisors held 980 shares of Jazz Pharmaceuticals worth $236K as of Q2 2026.
  • Jazz Pharmaceuticals was a new Concurrent Investment Advisors position in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1846 holding.
  • Concurrent Investment Advisors first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • Concurrent Investment Advisors's Jazz Pharmaceuticals position peaked at $701K in Q1 2024.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.